<DOC>
	<DOC>NCT00406601</DOC>
	<brief_summary>The aim of this study (*) is to evaluate the progression free survival rate at 6 months, response rate, overall disease control rate, overall survival of BAY-43-9006 in soft tissue sarcoma patients. (*) as per Protocol Amendment No. 1 of 16 April 2007 approved by local IEC on 24 July 2007</brief_summary>
	<brief_title>BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically documented, progressive, advanced or metastatic sarcoma after adjuvant and/or first line anthracyclinebased regimen; age &gt;=18 yrs; ECOG PS =2; at least 1 measurable target lesion; life expectancy &gt;=12 wks; adequate medullary liver and renal function; written informed consent. metastatic brain disease; pregnant or breastfeeding patients; serious infections.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>